1-2 of 2
Valdas Peceliunas, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Anders Waage, MD PhD, Valdas Peceliunas, MD, Fredrik Schjesvold, MDPhD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Mervi Putkonen, MD PhD, Kristina Carlson, MD, Einar Haukaas, MD, Marja Sankelo, MDPhD, Anu Partanen, MD PhD, Damian L. Szatkowski, MDPhDMSc, Markus Hansson, MD PhD, Anu Marttila, MD, Lucia Ahlberg, MD, Per Axelsson, MD, Birgitta Lauri, MD, Maija Helena Mikkola, MD, Conny Karlsson, MD, Johanna Abelsson, MD, Erik Ahlstrand, MD PhD, Anu Sikiö, MD, Monika Klimkowska, MD PhD, Reda Matuzeviciene, MD PhD, Mona Hoysaeter Fenstad, MD PhD, Sorella Ilveskero, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-138643
Published: 2020
Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Henrik Gregersen, MD PhD, Valdas Peceliunas, MD, Kari Remes, MD PhD, Fredrik H. Schjesvold, MD PhD, Niels Abildgaard, MD, Hareth Nahi, MD PhD, Niels Frost Andersen, MD PhD, Annette Juul Vangsted, MD PhD, Tobias Wirenfeldt Klausen, M.S., Carsten Helleberg, MD, Kristina Carlson, MD, Ulf Christian Frølund, MD, Per Axelsson, MD, Olga Stromberg, MD, Cecilie Hveding Blimark, PhD MD, Olle Linder, MD, Galina Tsykunova, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Nina Gulbrandsen
Journal: Blood
Blood (2019) 134 (Supplement_1): 601.
https://doi.org/10.1182/blood-2019-122141
Published: 2019